AG0302-COVID‑19

AG0302-COVID‑19 is an investigational vaccine for the prevention of COVID-19, the disease caused by the SARS-CoV-2 virus. The vaccine is being developed by AnGes, Inc., a Japanese biopharmaceutical company, in collaboration with Osaka University and Takara Bio.

Development

The development of AG0302-COVID‑19 began in early 2020, following the global outbreak of the COVID-19 pandemic. The vaccine is based on DNA vaccine technology, which uses a small, circular piece of DNA called a plasmid that has been engineered to produce a protein found in SARS-CoV-2.

Clinical Trials

The vaccine entered Phase I clinical trials in Japan in June 2020, with the aim of testing its safety and efficacy in a small group of volunteers. The results of these trials are yet to be published.

Mechanism of Action

AG0302-COVID‑19 works by introducing a piece of DNA into the body that encodes for a protein found in SARS-CoV-2. This protein triggers an immune response, which is intended to protect against future infection with the virus.

Potential Side Effects

As with all vaccines, AG0302-COVID‑19 may cause side effects. These are most likely to include common vaccine side effects such as pain at the injection site, fever, and muscle aches.

See Also

• COVID-19 vaccine
• COVID-19 pandemic
• SARS-CoV-2
• DNA vaccine

References

<references />

   This article is a  stub. You can help WikiMD by expanding it!

This article is a stub related to pharmacology. You can help WikiMD by expanding it!